Cor.At-X xCELLigence Cardio
Cor.At-X® cardiomyocytes are a customized version of Cor.At® cells for sole use in Roche's xCELLigence® RTCA Cardio instrument. The xCELLigence system provides a non-invasive, label-free way to continuously monitor cellular parameters such as viability, death, adhesion and proliferation. The system records the electrical impedance of cells grown on microelectrode arrays integrated into the bottom of each well of an E-Plate 96. Cor.At-X® cardiomyocytes are adapted to optimal adherence and stability in the impedance sensor-equipped E-Plate Cardio 96. One vial of cells is usually sufficient for one individual E-plate.
From the Roche xCELLigence® RTCA Cardio press release: ... "Cardiotoxicity is one of the most relevant parameters tested in drug development. The RTCA Cardio Instrument is the only 96 well, cardiotoxicity screening system on the market for continuous, real-time, label-free cardiomyocyte beating analysis. The instrument can be used in conjunction with cardiomyocytes derived from human or mouse stem cells for assessing the cardiac safety profile of lead compounds or drug candidates during drug development..."
Advantages Cor.At-X xCELLigence Cardio
- High puritiy – 100% cardiomyocytes, no de-differentiation.
- Well-characterized, authentic und reproducible cellular environment.
- Consistent performance – large lot sizes with minimal lot-to-lot variation.
- Predictive model – relevant cardiac physiology.
- Cryopreserved in vials.
- Adapted to the needs of the xCELLigence® RTCA Cardio instrument and the culture in the E-Plate Cardio 96.